2 Information about selpercatinib

Marketing authorisation indication

2.1 Selpercatinib (Retsevmo, Eli Lilly) has a conditional marketing authorisation 'for the treatment of adults with advanced RET fusion-positive non-small-cell lung cancer (NSCLC) who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.


2.3 The list price for 60 capsules of selpercatinib (80 mg) is £4,680 (excluding VAT; BNF online, accessed July 2021). The company's estimated cost for a 28‑day cycle of selpercatinib is £8,736.00.

2.4 The company has a commercial arrangement. This makes selpercatinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)